Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

PF-562271 (besylate)

PF-562271 (VS-6062) besylate is a potent ATP-competitive, reversible inhibitor of FAK and Pyk2 kinase, with an IC50 of 1.5 nM and 13 nM, respectively[1].

Product Specifications

CAS Number

[939791-38-5]

Product Name Alternative

VS-6062 (besylate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

FAK; Pyk2

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/PF-562271-besylate.html

Purity

99.17

Solubility

DMSO : 21.4 mg/mL (ultrasonic; warming) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CS(=O)(N(C)C1=NC=CC=C1CNC2=NC(NC3=CC4=C(NC(C4)=O)C=C3)=NC=C2C(F)(F)F)=O.O=S(C5=CC=CC=C5)(O)=O

Molecular Formula

C27H26F3N7O6S2

Molecular Weight

665.66

Precautions

H302, H315, H319, H335

References & Citations

[1]Roberts WG, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res, 2008, 68 (6), 1935-1944.|[2]Lim ST, et al. FERM control of FAK function: implications for cancer therapy. Cell Cycle, 2008, 7 (15), 2306-2314.|[3]Canel M, et al. Quantitative in vivo imaging of the effects of inhibiting integrin signaling via Src and FAK on cancer cell movement: effects on E-cadherin dynamics. Cancer Res, 2010, 70 (22), 9413-9422.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|University of Washington. 2025.|Am J Chin Med. 2025;53 (4) :1225-1240.|Anticancer Drugs. 2024 Jan 1;35 (1) :46-54.|bioRxiv. 2025 Apr 7:2025.04.01.646098.|bioRxiv. 2025 May 28.|Breast Cancer Res. 2024 Mar 19;26 (1) :48.|Cancer Med. 2025 Sep;14 (18) :e71227.|Cancer Res. 2013 May 1;73 (9) :2873-83.|Carbohydr Polym. 2024 Feb 15:326:121637.|Cell Death Dis. 2022 Sep 10;13 (9) :783.|Cell Death Dis. 2023 Feb 24;14 (2) :157.|Cell Discov. 2022 Sep 6;8 (1) :84.|Cell Rep. 2023 Oct 5;42 (10) :113213.|Cell Signal. 2025 Sep 10:136:112117.|Clin Cancer Res. 2019 Jul 15;25 (14) :4552-4566.|Environ Toxicol Pharmacol. 2023 Nov:104:104301.|Eur J Cell Biol. 2024 May 28;103 (2) :151427.|Harvard Medical School LINCS LIBRARY|Int J Cancer. 2015 Oct 1;137 (7) :1549-59.|Int J Surg. 2025 Sep 17.|J Nat Med. 2020 Sep;74 (4) :732-740.|Life Sci. 2021 Apr 1:270:119112.|Mol Biol Rep. 2025 May 14;52 (1) :458.|Nat Biomed Eng. 2025 Nov 3.|Practical Oncology Journal. 2015, 29 (5) : 444-449.|Res Sq. 2025 Jul 11.|Research Square Preprint. 2021 Dec.|Research Square Preprint. 2023 May 23.|Sci Rep. 2018 May 8;8 (1) :7228. |World J Gastroenterol. 2025 Jul 28;31 (28) :107361.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Mononervonin

MBS392873-01 25 mg

Mononervonin

Ask

Mononervonin

MBS392873-02 3x 25 mg

Mononervonin

Ask

Rabbit Polyclonal JAKMIP1 Antibody [mFluor Violet 450 SE]

NBP2-81959MFV450 0.1 mL

Rabbit Polyclonal JAKMIP1 Antibody [mFluor Violet 450 SE]

Ask

CAPSL (NM_144647) Human Recombinant Protein

PH36748M5 20 µg

CAPSL (NM_144647) Human Recombinant Protein

Ask